.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,516,896

« Back to Dashboard

Details for Patent: 5,516,896

Title: Biologically active B-chain homodimers
Abstract:Dimeric proteins having substantially the same biological activity as PDGF are disclosed. More specifically, the protein may have two substantially identical polypeptide chains, each of the chains being substantially homologous to the B-chain of PDGF. Alternatively, the protein may have two polypeptide chains that are substantially identical to the B-chain of PDGF. In addition, proteins comprising polypeptides that are variants or derivatives of the B-chain of PDGF are also disclosed. Therapeutic compositions containing these proteins and methods for enhancing the wound-healing process in warm-blooded animals are also disclosed.
Inventor(s): Murray; Mark J. (Seattle, WA), Kelly; James D. (Seattle, WA)
Assignee: ZymoGenetics, Inc. (Seattle, WA)
Filing Date:Jul 13, 1989
Application Number:07/381,096
Claims:1. A protein having two PDGF-B polypeptide chains, said chains having one or more of the following modifications:

(a) one or more amino acid substitutions of cysteine residues corresponding to residues 43, 49, 52, and 53 of the PDGF B chain;

(b) a deletion of 1 to 14 amino acids at the N-terminus of the protein; and

(c) a deletion of 1 to 9 amino acids at the C-terminus of the protein.

2. The protein of claim 1 wherein the cysteine residue corresponding to residue 43 is changed to serine.

3. The protein of claim 1 wherein the cysteine residue corresponding to residue 52 is changed to serine.

4. The protein of claim 1 wherein the cysteine residue corresponding to residue 53 is changed to serine.

5. The protein of claim 1 wherein said polypeptide chains comprise the B-chain of PDGF from amino acid 15 to amino acid 109, optionally having one or more amino acid substitutions of cysteine residues corresponding to residues 43, 49, 52, and 53 of the PDGF B chain.

6. The protein of claim 1 wherein said polypeptide chains comprise the B-chain of PDGF from amino acid 15 to amino acid 101, optionally having one or more amino acid substitutions of cysteine residues corresponding to residues 43, 49, 52, and 53 of the PDGF B chain.

7. The protein of claim 1 wherein said polypeptide chains comprise the B-chain of PDGF from amino acid 1 to amino acid 101, optionally having one or more amino acid substitutions of cysteine residues corresponding to residues 43, 49, 52, and 53 of the PDGF B chain.

8. The protein according to claim 5, 6, or 7, further comprising one or more amino acid substitutions of cysteine residues corresponding to residues 43, 49, 52, and 53 of the PDGF B chain.

9. A therapeutic composition comprising a protein having two PDGF-B polypeptide chains, said chains having one or more of the following modifications:

(a) one or more amino acid substitutions of cysteine residues corresponding to residues 43, 49, 52, and 53 of the PDGF B chain;

(b) a deletion of 1 to 14 amino acids at the N-terminus of the protein; and

(c) a deletion of 1 to 9 amino acids at the C-terminus of the protein, said protein being chemotactic or mitogenic for fibroblasts, and a physiologically acceptable carrier or diluent.

10. The therapeutic composition of claim 9 wherein the cysteine residue corresponding to residue 43 is changed to serine.

11. The therapeutic composition of claim 9 wherein the cysteine residue corresponding to residue 52 is changed to serine.

12. The therapeutic composition of claim 9 wherein the cysteine residue corresponding to residue 53 is changed to serine.

13. The therapeutic composition of claim 9 wherein said polypeptide chains comprise the B-chain of PDGF from amino acid 15 to amino acid 109, optionally having one or more amino acid substitutions of cysteine residues corresponding to residues 43, 49, 52, and 53 of the PDGF B chain.

14. The therapeutic composition of claim 9 wherein said polypeptide chains comprise the B-chain of PDGF from amino acid 15 to amino acid 101, optionally having one or more amino acid substitutions of cysteine residues corresponding to residues 43, 49, 52, and 53 of the PDGF B chain.

15. The therapeutic composition of claim 9 wherein polypeptide chains comprise the B-chain of PDGF from amino acid 1 to amino acid 101, optionally having one or more amino acid substitutions of cysteine residues corresponding to residues 43, 49, 52, and 53 of the PDGF B chain.

16. The therapeutic composition according to claim 13, 14, or 15, further comprising one or more amino acid substitutions of cysteine residues corresponding to residues 43, 49, 52, and 53 of the PDGF B chain.

17. The therapeutic composition of claim 9 wherein said protein is present in a concentration of from about 1 to 50 micrograms per milliliter of total volume.

18. The therapeutic composition of claim 9 wherein said carrier or diluent is selected from the group consisting of albumin, sterile water, and saline.

19. The therapeutic composition of claim 18, including an adjuvant.

20. The therapeutic composition of claim 19 wherein said adjuvant is selected from the group consisting of collagen, hyaluronic acid, fibronectin, factor XIII, and an antibiotic.

21. A method for enhancing the wound-healing process in warm-blooded animals, comprising administering to the animal a therapeutically effective amount of a protein having two PDGF-B polypeptide chains, said chains having one or more of the following modifications:

(a) one or more amino acid substitutions of cysteine residues corresponding to residues 43, 49, 52, and 53 of the PDGF B chain;

(b) a deletion of 1 to 14 amino acids at the N-terminus of the protein; and

(c) a deletion of 1 to 9 amino acids at the C-terminus of the protein, said protein being chemotactic and mitogenic for fibroblasts, and a physiologically acceptable carrier or diluent.

22. The method of claim 21 wherein the cysteine residue corresponding to residue 43 is changed to serine.

23. The method of claim 21 wherein the cysteine residue corresponding to residue 52 is changed to serine.

24. The method of claim 21 wherein the cysteine residue corresponding to residue 53 is changed to serine.

25. The method of claim 21 wherein said polypeptide chains comprise the B-chain of PDGF from amino acid 15 to amino acid 109, optionally having one or more amino acid substitutions of cysteine residues corresponding to residues 43, 49, 52, and 53 of the PDGF B chain.

26. The method of claim 21 wherein said polypeptide chains comprise the B-chain of PDGF from amino acid 15 to amino acid 101, optionally having one or more amino acid substitutions of cysteine residues corresponding to residues 43, 49, 52, and 53 of the PDGF B chain.

27. The method of claim 21 wherein said polypeptide chains comprise the B-chain of PDGF from amino acid 1 to amino acid 101, optionally having one or more amino acid substitutions of cysteine residues corresponding to residues 43, 49, 52, and 53 of the PDGF B chain.

28. The method according to claim 25, 26, or 27, further comprising one or more amino acid substitutions of cysteine residues corresponding to residues 43, 49, 52, and 53 of the PDGF B chain.

29. The method of claim 21 wherein said protein is present in a concentration of from about 1 to 50 micrograms per milliliter of total volume.

30. The method of claim 21 wherein said carrier or diluent is selected from the group consisting of albumin, sterile water, and saline.

31. The method of claim 21 wherein said protein and physiologically acceptable carrier or diluent is administered topically.

32. The method of claim 21, including administering an adjuvant.

33. The method of claim 32 wherein said adjuvant is selected from the group consisting of collagen, hyaluronic acid, fibronectin, factor XIII, and antibiotics.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc